(Q43143677)

English

Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms

scientific article published on 4 March 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

James A. McCubrey

16

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

author name string

A M Martelli

1

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

V Papa

2

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

P L Tazzari

3

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

F Ricci

4

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

C Evangelisti

5

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

F Chiarini

6

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

C Grimaldi

7

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

A Cappellini

8

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

G Martinelli

9

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

E Ottaviani

10

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

P Pagliaro

11

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

S Horn

12

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

J Bäsecke

13

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

H Eibl

15

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

publication date

4 March 2010

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

687-698

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

https://scigraph.springernature.com/pub.10.1038/leu.2010.32

0 references

Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

New cytostatics with experimentally different toxic profiles

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

Perifosine: update on a novel Akt inhibitor.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

Combination effects of alkylphosphocholines and gemcitabine in malignant and normal hematopoietic cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

Erufosine, a novel alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other antileukemic drugs

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-cell acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

The minimal instrumentation requirements for Hoechst side population analysis: stem cell analysis on low-cost flow cytometry platforms

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

Identification of the critical features of a small peptide inhibitor of JNK activity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

A monoclonal antibody to visualize PtdIns(3,4,5)P(3) in cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

A cholesterol-regulated PP2A/HePTP complex with dual specificity ERK1/2 phosphatase activity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

Aberrant early-phase ERK inactivation impedes neuronal function in fragile X syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

Hydrogen peroxide-induced neuronal apoptosis is associated with inhibition of protein phosphatase 2A and 5, leading to activation of MAPK pathway

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

Protein phosphatase 2A inactivates Bcl2's antiapoptotic function by dephosphorylation and up-regulation of Bcl2-p53 binding

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

Novel role for JNK as a stress-activated Bcl2 kinase

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

Inhibition of MEK signaling enhances the ability of cytarabine to induce growth arrest and apoptosis of acute myelogenous leukemia cells.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

Activation of RAF-1 through Ras and protein kinase Calpha mediates 1alpha,25(OH)2-vitamin D3 regulation of the mitogen-activated protein kinase pathway in muscle cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

Mitochondrial protein phosphatase 2A regulates cell death induced by simulated ischemia in kidney NRK-52E cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

Targeting the leukemic stem cell: the Holy Grail of leukemia therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

Extended flow cytometry characterization of normal bone marrow progenitor cells by simultaneous detection of aldehyde dehydrogenase and early hematopoietic antigens: implication for erythroid differentiation studies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

Akt signaling regulates side population cell phenotype via Bcrp1 translocation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

c-Jun N-terminal kinase activation failure is a new mechanism of anthracycline resistance in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

21 January 2018

Experimental studies on the role of alkyl lysophospholipids in autologous bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

7 January 2021

based on heuristic

inferred from DOI database lookup

Miltefosine for visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

7 January 2021

based on heuristic

inferred from DOI database lookup

PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

7 January 2021

based on heuristic

inferred from DOI database lookup

PKR is activated in MDS patients and its subcellular localization depends on disease severity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

7 January 2021

based on heuristic

inferred from DOI database lookup

Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

7 January 2021

based on heuristic

inferred from DOI database lookup

A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

7 January 2021

based on heuristic

inferred from DOI database lookup

Bcl-2 protects endothelial cells against gamma-radiation via a Raf-MEK-ERK-survivin signaling pathway that is independent of cytochrome c release

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

7 January 2021

based on heuristic

inferred from DOI database lookup

Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

7 January 2021

based on heuristic

inferred from DOI database lookup

Bryostatin-I: an antineoplastic treasure from the deep?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.32

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2010.32

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43143677&oldid=1981581436"